The U.S. Food and Drug Administration recently urged drug manufacturer, AstraZeneca, to update the label of its blockbuster anti-psychotic medication, Seroquel, following the agency’s receipt of almost 17 individual reports from patients experiencing heart problems as a result of taking more than the recommended dose of the drug.

Following the FDA’s request, AstraZeneca released a statement that it would, in fact, add a warning to the drug’s label about the risk of potentially life-threatening heart rhythm problems when combined with certain other medications, as well as when taken in excess.

Seroquel is a popular anti-psychotic medication approved for use in the treatment of schizophrenia, bi-polar disorder and severe depression. The drug is a top-selling product for AstraZeneca, generating more than $5 billion in sales last year. Seroquel is often prescribed for off-label uses not previously approved by the FDA, such as autism, compulsive disorders and obsessive dementia. It has also been the subject of heated legal battles over the years, one of which resulted in a $520 million settlement pay-out by AstraZeneca, following government claims the company was engaging in illegal marketing activities.

RESULTS & SETTLEMENTS

Frank M. Eidson P.A. has been tirelessly representing the rights of Central Florida victims since 1989.

$4.2 Million

Auto Accident

$2.3 Million

Workers Comp Case

$5.65 Million

Auto Accident


Free, No Obligation Case Review.

Fill out our contact form below for your free, no obligation case review.

  • This field is for validation purposes and should be left unchanged.

Help provide wounded servicemen and women with therapeutic outdoor adventures. Like our Facebook page and we'll contribute $1 to Wounded Warriors Outdoors.

Contact Our Orlando Attorney

If you have been injured in an accident, turn to Frank M. Eidson P.A. Whether your case is a simple collision or a complicated auto wrongful death case, contact personal injury lawyer Frank Eidson today to schedule your free consultation.

407-245-2887